These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32434404)

  • 41. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
    Al-Zaidy SA; Mendell JR
    Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.
    Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A
    Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians.
    Ramdas S; Oskoui M; Servais L
    Drugs; 2024 Jul; 84(7):747-762. PubMed ID: 38878146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in the Therapy of Spinal Muscular Atrophy.
    Klotz J; Tesi Rocha C; Dunaway Young S; Duong T; Buu M; Sampson J; Day JW
    J Pediatr; 2021 Sep; 236():13-20.e1. PubMed ID: 34197889
    [No Abstract]   [Full Text] [Related]  

  • 45. Modern approaches in gene therapy of motor neuron diseases.
    Zakharova M
    Med Res Rev; 2021 Sep; 41(5):2634-2655. PubMed ID: 32638429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program.
    Chand DH; Mitchell S; Sun R; LaMarca N; Reyna SP; Sutter T
    Pediatr Neurol; 2022 Jul; 132():27-32. PubMed ID: 35605311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy.
    Matesanz SE; Battista V; Flickinger J; Jones JN; Kichula EA
    Pediatr Neurol; 2021 May; 118():1-5. PubMed ID: 33677142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The respiratory impact of novel therapies for spinal muscular atrophy.
    Paul GR; Gushue C; Kotha K; Shell R
    Pediatr Pulmonol; 2021 Apr; 56(4):721-728. PubMed ID: 33098622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy.
    Scheijmans FEV; Zomers ML; Fadaei S; Onrust MR; van der Graaf R; Delden JJMV; van der Pol WL; van Thiel GJMW
    BMC Health Serv Res; 2022 Nov; 22(1):1320. PubMed ID: 36333803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies.
    Garrison LP; Jiao B; Dabbous O
    J Manag Care Spec Pharm; 2021 May; 27(5):674-681. PubMed ID: 33908277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e1-e2. PubMed ID: 34544108
    [No Abstract]   [Full Text] [Related]  

  • 53. [Our initial experiences with intravenous gene therapy for spinal muscular atrophy in children].
    Mikos B; Gergely A; Balázsfi R; Bányász E; Gyömörei B; Hantos M; Czelecz J; Jakus R; Kárász H; Zilahy M; Molnár E; Paraicz É; Csohány Á; Szénási F; Vendégh L; Fogarasi A; Velkey G
    Orv Hetil; 2020 Oct; 161(42):1806-1816. PubMed ID: 33070118
    [No Abstract]   [Full Text] [Related]  

  • 54. Spinal Muscular Atrophy.
    Nicolau S; Waldrop MA; Connolly AM; Mendell JR
    Semin Pediatr Neurol; 2021 Apr; 37():100878. PubMed ID: 33892848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Treatment Options in Neurology-SMA Therapeutics.
    Waldrop MA; Kolb SJ
    Curr Treat Options Neurol; 2019 Apr; 21(6):25. PubMed ID: 31037425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1.
    Oechsel KF; Cartwright MS
    Muscle Nerve; 2021 Oct; 64(4):487-490. PubMed ID: 34287987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy.
    Wiedmann L; Cairns J
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):469-482. PubMed ID: 36947403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nusinersen: A Treatment for Spinal Muscular Atrophy.
    Claborn MK; Stevens DL; Walker CK; Gildon BL
    Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.